Premium
Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
Author(s) -
Gómez Montse,
Guillem Vicent,
Pereira Arturo,
FerrerMarín Francisca,
ÁlvarezLarrán Alberto,
Kerguelen Ana,
Estrada Natàlia,
MartínezLópez Joaquín,
Angona Anna,
Amat Paula,
Navarro Blanca,
Besses Carles,
HernándezBoluda JuanCarlos
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12588
Subject(s) - medicine , essential thrombocythemia , polycythemia vera , skin cancer , incidence (geometry) , cumulative incidence , cancer , population , oncology , gastroenterology , cohort , physics , environmental health , optics
Objectives Population‐based studies have reported an increased incidence of skin cancer in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We have examined the risk factors for non‐melanoma skin cancer (NMSC) in patients diagnosed with ET or PV during 1973–2012. Methods A case–control study was performed to compare the clinical and treatment‐related data of 51 ET/PV patients who had NMSC with that of 401 patients who did not. We also evaluated whether polymorphisms in 12 genes involved in DNA integrity predisposed to NMSC. Results By multivariate logistic regression analysis, risk factors for NMSC were older age (OR: 1.7, 95% CI: 1.3–2.1, P < 0.001), male sex (OR: 2.1, 95% CI: 1.1–3.8, P = 0.023), higher cumulated hydroxycarbamide dose (OR: 1.3, 95% CI: 1.1–1.7, P = 0.017), and busulphan exposure (OR: 3.2, 95% CI: 1.05–10.0, P = 0.041). On the time‐to‐event prognostic model, factors independently associated with increased cumulative incidence of NMSC were age (5% increased risk per year; P < 0.001), male sex (91% increased risk; P = 0.022), and hydroxycarbamide exposure (22% increased risk; P = 0.065). No susceptibility gene variant was identified. Conclusions These findings suggest that the risk to develop NMSC in ET/PV patients results from the combined effect of common risk factors (age, male sex) together with cytoreductive treatment.